Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.39 +5.5%	$2.55	$1.78 ▼ $10.14	$49.82M	0.7	266,570 shs	73,586 shs
CHRS Coherus Oncology	$0.80 +0.7%	$0.83	$0.66 ▼ $2.43	$92.86M	0.86	2.67 million shs	679,404 shs
CRTX Cortexyme	$1.61 +0.6%	$1.17	$1.78 ▼ $40.66	$48.54M	1.4	620,672 shs	138,723 shs
INBX Inhibrx Biosciences	$16.29 +3.5%	$13.37	$10.80 ▼ $17.79	$235.81M	-0.04	95,858 shs	53,380 shs
MESO Mesoblast	$10.79 -0.6%	$11.33	$5.78 ▼ $22.00	$1.38B	2.39	277,165 shs	208,906 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+5.53%	-4.22%	-4.98%	-38.21%	-66.55%
CHRS Coherus Oncology	+0.74%	+9.34%	+2.69%	+2.46%	-42.37%
CRTX Cortexyme	+5.26%	+10.34%	+50.94%	+21.21%	+128.34%
INBX Inhibrx Biosciences	+3.46%	+10.11%	+20.36%	+22.08%	+21.17%
MESO Mesoblast	-0.64%	+0.37%	+2.27%	+2.08%	+58.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.2542 of 5 stars	3.4	3.0	0.0	4.8	1.0	2.5	0.6
CHRS Coherus Oncology	3.7583 of 5 stars	3.3	1.0	0.0	4.5	0.6	2.5	0.6
CRTX Cortexyme	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	1.2603 of 5 stars	0.0	1.0	0.0	4.6	0.0	2.5	1.3
MESO Mesoblast	2.4078 of 5 stars	3.5	1.0	0.0	0.0	3.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	897.90% Upside
CHRS Coherus Oncology	2.67	Moderate Buy	$4.68	484.69% Upside
CRTX Cortexyme	0.00	N/A	N/A	N/A
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
MESO Mesoblast	3.00	Buy	$18.00	66.82% Upside

Current Analyst Ratings Breakdown

Latest MESO, INBX, ADVM, CRTX, and CHRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
4/29/2025	CHRS Coherus Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/24/2025	CHRS Coherus Oncology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50 ➝ $1.05
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00
4/16/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$10.00 ➝ $5.00
4/16/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	49.82	N/A	N/A	$3.40 per share	0.70
CHRS Coherus Oncology	$272.25M	0.34	$0.29 per share	2.73	($1.14) per share	-0.70
CRTX Cortexyme	N/A	N/A	N/A	N/A	$3.97 per share	N/A
INBX Inhibrx Biosciences	$200K	1,179.03	$125.27 per share	0.13	$9.23 per share	1.76
MESO Mesoblast	$5.90M	233.69	N/A	N/A	$4.21 per share	2.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
CHRS Coherus Oncology	$28.51M	-$1.13	N/A	N/A	N/A	-66.30%	N/A	-26.51%	8/6/2025 (Estimated)
CRTX Cortexyme	-$89.94M	-$2.97	N/A	N/A	N/A	N/A	-70.96%	-63.53%	N/A
INBX Inhibrx Biosciences	$1.69B	$116.75	0.14	N/A	N/A	N/A	-85.12%	-58.90%	8/12/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)

Latest MESO, INBX, ADVM, CRTX, and CHRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/12/2025	Q1 2025	CHRS Coherus Oncology	-$0.31	-$0.35	-$0.04	-$0.49	$59.79 million	$7.60 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
CRTX Cortexyme	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
CHRS Coherus Oncology	N/A	1.22	1.20
CRTX Cortexyme	N/A	9.92	9.92
INBX Inhibrx Biosciences	1.04	5.12	5.12
MESO Mesoblast	0.22	0.96	0.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
CHRS Coherus Oncology	72.82%
CRTX Cortexyme	63.18%
INBX Inhibrx Biosciences	82.46%
MESO Mesoblast	1.43%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
CHRS Coherus Oncology	8.08%
CRTX Cortexyme	27.90%
INBX Inhibrx Biosciences	17.09%
MESO Mesoblast	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
CHRS Coherus Oncology	330	115.93 million	106.57 million	Optionable
CRTX Cortexyme	55	30.15 million	21.74 million	Not Optionable
INBX Inhibrx Biosciences	166	14.48 million	12.00 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable

MESO, INBX, ADVM, CRTX, and CHRS Headlines

Recent News About These Companies

Mesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?

July 2 at 12:18 PM | marketbeat.com

Mesoblast Shares Surge on FDA Alignment

July 1 at 10:55 PM | sharecafe.com.auS

Mesoblast, FDA agree on marketing application for cell therapy

July 1 at 10:55 PM | msn.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?

July 1 at 10:56 AM | marketbeat.com

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

July 1 at 8:46 AM | benzinga.com

Financial Survey: Mesoblast (NASDAQ:MESO) vs. Rallybio (NASDAQ:RLYB)

July 1 at 4:19 AM | americanbankingnews.com

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

June 30, 2025 | globenewswire.com

Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil

June 29, 2025 | msn.com

Mesoblast (NASDAQ:MESO) Shares Down 4.2% - Here's What Happened

June 23, 2025 | marketbeat.com

Mesoblast Limited (MSB.AX)

June 22, 2025 | finance.yahoo.com

Prosperity Wealth Management Inc. Has $608,000 Stock Position in Mesoblast Limited (NASDAQ:MESO)

June 18, 2025 | marketbeat.com

Mesoblast Limited (NASDAQ:MESO) Shares Purchased by GAMMA Investing LLC

June 16, 2025 | marketbeat.com

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’

June 12, 2025 | msn.com

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

June 11, 2025 | globenewswire.com

Mesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?

June 11, 2025 | marketbeat.com

Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval

June 10, 2025 | finance.yahoo.com

Mesoblast (NASDAQ:MESO) Trading Up 6.2% - Here's What Happened

June 10, 2025 | marketbeat.com

Cantor Fitzgerald Predicts Mesoblast FY2026 Earnings

June 10, 2025 | marketbeat.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Which S&P 500 Move Matters?

May 27, 2025 | msn.com

HotCopper Highlights Week 20: Mesoblast FDA miss; Larvotto posts tungsten, Melbana & More

May 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, INBX, ADVM, CRTX, and CHRS Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.38 +0.13 (+5.53%)

Closing price 07/3/2025 02:21 PM Eastern

Extended Trading

$2.33 -0.05 (-2.31%)

As of 07/3/2025 04:01 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Coherus Oncology NASDAQ:CHRS

$0.80 +0.01 (+0.74%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$0.78 -0.03 (-3.12%)

As of 07/3/2025 04:55 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Cortexyme NASDAQ:CRTX

$1.61 +0.01 (+0.63%)

As of 07/3/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Inhibrx Biosciences NASDAQ:INBX

$16.28 +0.55 (+3.46%)

As of 07/3/2025 01:04 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Mesoblast NASDAQ:MESO

$10.79 -0.07 (-0.64%)

Closing price 07/3/2025 03:26 PM Eastern

Extended Trading

$10.79 0.00 (0.00%)

As of 07/3/2025 04:15 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time